SCHEMBL629894

SCHEMBL629894

COc1ccc(C[C@H](NC(=O)[C@@H]2CCCCN2C(=O)OCc2ccccc2)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
ALDH1A1 P00352 1/20 0.56
TP53 P04637 1/20 0.55
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
CACNA1B Q00975 5/20 0.51
YAP1 P46937 1/20 0.51
CMA1 P23946 1/20 0.50
ACE P12821 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CTSB P07858 1/20 0.47
CTSS P25774 1/20 0.47
CTSK P43235 1/20 0.47
PREP P48147 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL630484 1.00 CTRB1 (0.56) CTRB1NPSR1ALDH1A1TP53KDM4E
Iodomethane SCHEMBL5183466 0.98 CTRB1 (0.55) CTRB1NPSR1ALDH1A1TP53KDM4E
SCHEMBL630940 0.92 CTRB1 (0.59) CTRB1NPSR1KDM4ELMNACACNA1B
SCHEMBL630348 0.92 CTRB1 (0.59) CTRB1NPSR1KDM4ELMNACACNA1B
SCHEMBL17833223 0.84 CTRB1 (0.60) CTRB1NPSR1ALDH1A1TP53KDM4E
SCHEMBL21429800 0.84 YAP1 (0.59) CTRB1NPSR1KDM4ELMNAYAP1
SCHEMBL19639228 0.84 CTRB1 (0.60) CTRB1NPSR1ALDH1A1TP53KDM4E
SCHEMBL13206953 0.83 CACNA1B (0.53) ALDH1A1LMNACACNA1BYAP1ACE
SCHEMBL19639223 0.82 CTRB1 (0.67) CTRB1NPSR1ALDH1A1TP53KDM4E
SCHEMBL28067687 0.82 ACE (0.56) CTRB1YAP1CMA1ACEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778637-B1 FKBP-binding composition and pharmaceutical use thereof AVENTIS PHARMA INC (US) 2012-02-22 EP disclosed
US-7777042-B2 N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof AVENTIS PHARMACEUTICALS INC. (US) 2010-08-17 US disclosed
US-7777042-B2 N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof AVENTIS PHARMACEUTICALS INC. (US) 2010-08-17 US disclosed
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2008-06-12 US disclosed
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2008-06-12 US disclosed
EP-1778637-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF Aventis Pharmaceuticals, Inc. (US) 2007-05-02 EP disclosed
WO-2006012256-A2 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF AVENTIS PHARMACEUTICALS INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139556-A1 FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF FKBP1A, FKBP1B, FKBP3 CTRB1 2442/4885NPSR1 649/4885ALDH1A1 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.